Company Overview and News

77
DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus

1h zacks
Duchenne muscular dystrophy (“DMD”) is a rare genetic disease and a severe form of muscular dystrophy, primarily affecting males. It progressively weakens and degenerates skeletal and heart muscles.
PFZ SLDB CATB PTCT SRPT 500680 PFE PFIZER

169
Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

2018-06-21 seekingalpha
Anika Therapeutics (ANIK) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (‘OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combination anti-inflammatory formula that combines hyaluronic acid (‘HA) with a steroid (triamcinolone hexacetonide). HA serves as a lubricant for arthritic joints.
NTLA CYAD AMGN ANIK PSTI CRSP SRPT MDWD CANF AMPH NVUS RSLS ALXN ALNA KALA CYAD CLBS PRTA PSTIW

19
Sarepta Therapeutics: Chasing The Good News

2018-06-21 seekingalpha
While the latest preliminary research results are based on a very small sample, indications look very promising.
SRPT

126
Sarepta Pharma Pushes Two Biotech ETFs to New Highs

2018-06-20 zacks
Sarepta Therapeutics Inc. (SRPT - Free Report) was a star performer in Tuesday’s trading session, as the stock skyrocketed as much as 57.7% to a new high of $176.50 but closed a little lower, rising 36.8% (read: 4 Sector ETFs That Crushed S&P 500 in 9-Year Bull Run). The surge propelled the company’s market cap from $6.9 billion to more than $9 billion, making it the fifth most valuable drugmaker headquartered in Massachusetts, behind Biogen (BIIB - Free Report) , Vertex Pharmaceuticals (VRTX - Free Report) , Alexion Pharmaceuticals (ALXN - Free Report) and Alnylam Pharmaceuticals (ALNY - Free Report) .
SBIO VRTX ALXN BIIB SLDB SRPT IBB ALNY

313
A Short Case For A Longer Term!

2018-06-20 seekingalpha
Most investors should favor a longer-term time frame as the markets again record new highs after recovering from the first quarter pullback.
CRC ADAP ECYT LOXO NBIX ARWR SRPT TRXC CHGG SUPN RGNX ARNA TWLO IMMU NDAQ MRTX HEAR TTD

19
Sarepta Therapeutics Stock Climbed 80% on Spectacular DMD Therapy Update

2018-06-20 biospace
Sarepta Therapeutics shares rocketed by as much as 80 percent yesterday after the company released interim data on its experimental gene therapy AAVrh74.MHCK7.micro-Dystrophin for Duchenne muscular dystrophy (DMD).
SRPT

30
Sarepta's Stock Soars on Encouraging Gene Therapy Results

2018-06-20 zacks
Sarepta Therapeutics, Inc. (SRPT - Free Report) shares soared 37% on Tuesday after it announced promising results from an early-stage study, evaluating its gene therapy as a treatment for patients with Duchenne muscular dystrophy (DMD)
SLDB PTCT SRPT PFE

139
Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash

2018-06-20 zacks
The biotech sector was in focus with regular pipeline updates. While Sarepta Therapeutics, Inc. (SRPT - Free Report) and Solid Biosciences (SLDB - Free Report) gained on positive data, Anika Therapeutics, Inc. (ANIK - Free Report) and Ziopharm Oncology, Inc. (ZIOP - Free Report) declined on dismal results.
ZIOP AMGN ALXN SLDB ANIK SRPT

19
US stocks tumble on trade war fears

2018-06-19 channelnewsasia
NEW YORK: Wall Street stocks were under pressure for a third session in a row on Tuesday (Jun 19), joining a global selloff on heightened fears that US-China confrontations will mushroom into a trade war.
SRPT

19
Why Sarepta Shares Are Skyrocketing

2018-06-19 247wallst
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares skyrocketed on Tuesday after the firm presented positive preliminary results from its midstage Duchenne muscular dystrophy (DMD) trial. Specifically, the results came from Sarepta’s Phase 1/2a gene therapy clinical trial assessing AAVrh74.MHCK7.micro-Dystrophin in individuals with DMD.
SRPT

19
Sarepta stock soars as early-stage gene therapy data shows promise - Channel NewsAsia

2018-06-19 channelnewsasia
REUTERS: Sarepta Therapeutics Inc reported promising results on Tuesday from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy (DMD), driving the company's shares up 60 percent.
SRPT

20
Sarepta stock soars as early-stage gene therapy data shows promise

2018-06-19 reuters
(Reuters) - Sarepta Therapeutics Inc reported promising results on Tuesday from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy (DMD), driving the company’s shares up 60 percent.
SRPT

19
SRPT / Sarepta Therapeutics, Inc. 8-K (Current Report)

2018-06-19 sec.gov
srpt-8k_20180619.htm
SRPT

19
SRPT: Sarepta Therapeutics Inc - Stock Quote and News - CNBC

2018-06-19 cnbc
Like all ChartIQ markers, the object itself is managed by the chart, so when you scroll the chart the object moves with you. It is also destroyed automatically for you when the symbol is changed.
SRPT

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

12h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 803607100